Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994-2005

Eye

Volumn 23, Issue 5, 2009, Pages 1098-1110

  Owen, C G ^a   Carey, I M ^a   De Wilde, S ^a   Whincup, P H ^a   Wormald, R ^b   Cook, D G ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Compliance; Persistence; Treatment for glaucoma

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST PLUS TIMOLOL; PROSTAGLANDIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG TREATMENT FAILURE; ELECTRONIC MEDICAL RECORD; FEMALE; GENDER; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT IDENTIFICATION; PRESCRIPTION; SOCIAL ASPECT; TREATMENT DURATION; TREATMENT OUTCOME; TREND STUDY; UNITED KINGDOM;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GLAUCOMA; GREAT BRITAIN; HUMANS; MALE; MEDICAL RECORDS; MEDICATION ADHERENCE; MIDDLE AGED; OCULAR HYPERTENSION; PROPORTIONAL HAZARDS MODELS; PROSTAGLANDINS;

EID: 65949094353     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.213     Document Type: Article

References (48)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90(3): 262-267.
2. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci 2006; 47(10): 4254-4261.
3. Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ 2008; 86(1): 63-70.
4. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120(10): 1268-1279.
5. Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 1993; 116(2): 176-181.
6. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003; 12(5): 393-398.
7. Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 2005; 16(2): 114-121.
8. Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther 2000; 22(2): 167-208.
9. Kirwan JF, Nightingale JA, Bunce C, Wormald R. Beta-blockers for glaucoma and excess risk of airways obstruction: population based cohort study. BMJ 2002; 325(7377): 1396-1397.
10. Gandolfi SA, Chetta A, Cimino L, Mora P, Sangermani C, Tardini MG. Bronchial reactivity in healthy individuals undergoing long-term topical treatment with beta-blockers. Arch Ophthalmol 2005; 123(1): 35-38.
11. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004; 19(4): 357-362.
12. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23(8): 1296-1310.
13. Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol 1986; 101(5): 524-530.
14. Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007; 144(4): 533-540.
15. Wilensky J, Fiscella RG, Carlson AM, Morris LS, Walt J. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006; 141(1 Suppl): S28-S33.
16. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 2004; 137(1 Suppl): S13-S16.
17. Zhou Z, Althin R, Sforzolini BS, Dhawan R. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Br J Ophthalmol 2004; 88(11): 1391-1394.
18. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004; 137(1 Suppl): S3-12.
19. Owen CG, Carey IM, De WS, Whincup PH, Wormald R, Cook DG. The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003. Br J Ophthalmol 2006; 90(7): 861-868.
20. Carey IM, Cook DG, De WS, Bremner SA, Richards N, Caine S et al. Developing a large electronic primary care database (Doctor's Independent Network) for research. Int J Med Inform 2004; 73(5): 443-453.
21. Carey IM, Cook DG, De Wilde S, Bremner SA, Richards N, Caine S et al. Implications of the problem orientated medical record (POMR) for research using electronic GP databases: a comparison of the Doctors Independent Network Database (DIN) and the General Practice Research Database (GPRD). BMC Fam Pract 2003; 4(1): 14.
22. De Wilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Strachan DP et al. A comparison of the recording of 30 common childhood conditions in the Doctor0s Independent Network and General Practice Research Databases. Health Stat Q 2004; 22): 21-31.
23. CACI. ACORN 2003 User Guide 2004. http://www.caci. co.uk/pdfs/new%20acorn%20brochure.pdf. (Accessed December 2007).
24. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005; 140(4): 598-606.
25. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
26. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG (eds). Systemative Reviews in Health Care: Meta-Analysis in Context, 2nd ed BMJ Books: London, 2001, pp 285-312.
27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-634.
28. Light RJ, Pillemar DB. Summing Up: The Science of Reviewing Research. Harvard University Press: Cambridge, MA, USA, 1984.
29. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50(4): 1088-1101.
30. Dasgupta S, Oates V, Bookhart BK, Vaziri B, Schwartz GF, Mozaffari E. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care 2002; 8(10 Suppl): S255-S261.
31. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol 2003; 13(Suppl 4): S44-S52.
32. Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care 2002; 8(10 Suppl): S271-S277.
33. Spooner JJ, Bullano MF, Ikeda LI, Cockerham TR, Waugh WJ, Johnson T et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care 2002; 8(10 Suppl): S262-S270.
34. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353(5): 487-497.
35. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288(4): 455-461.
36. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147-1152.
37. DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care 2007; 45(6): 521-528.
38. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40(9): 794-811.
39. Friedman DS, Nordstrom B, Mozaffari E, Quigley HA. Variations in treatment among adult-onset open-angle glaucoma patients. Ophthalmology 2005; 112(9): 1494-1499.
40. Fraser S, Bunce C, Wormald R, Brunner E. Deprivation and late presentation of glaucoma: case-control study. BMJ 2001; 322(7287): 639-643.
41. Bateman DN, Clark R, Azuara-Blanco A, Bain M, Forrest J. The impact of new drugs on management of glaucoma in Scotland: observational study. BMJ 2001; 323(7326): 1401-1402.
42. Hedman K, Alm A, Gross RL. Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J Glaucoma 2003; 12(6): 463-465.
43. Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004; 49(Suppl 1): S45-S52.
44. Schwartz GF, Platt R. Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications. Am J Manag Care 2002; 8(10 Suppl): S278-S280.
45. Lee PP, Walt JG, Chiang TH, Guckian A, Keener J. A gap analysis approach to assess patient persistence with glaucoma medication. Am J Ophthalmol 2007; 144(4): 520-524.
46. Schwartz GF, Platt R, Reardon G, Mychaskiw MA. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology 2007; 114(4): 648-652.
47. Friedman DS, Quigley HA, Gelb L, Tan J, Margolis J, Shah SN et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci 2007; 48(11): 5052-5057.
48. Quigley HA, Friedman DS, Hahn SR. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology 2007; 114(9): 1599-1606.